Surrozen (NASDAQ:SRZN) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Surrozen (NASDAQ:SRZNFree Report) in a research note published on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

Separately, Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Friday, January 3rd.

Read Our Latest Stock Report on SRZN

Surrozen Trading Up 7.3 %

Shares of NASDAQ SRZN opened at $12.07 on Thursday. The firm’s 50 day simple moving average is $11.51 and its two-hundred day simple moving average is $10.12. Surrozen has a one year low of $6.00 and a one year high of $18.17.

Surrozen (NASDAQ:SRZNGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter.

Institutional Investors Weigh In On Surrozen

A hedge fund recently raised its stake in Surrozen stock. Stonepine Capital Management LLC raised its position in shares of Surrozen, Inc. (NASDAQ:SRZNFree Report) by 66.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 110,000 shares of the company’s stock after acquiring an additional 43,916 shares during the quarter. Surrozen makes up approximately 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 24th largest position. Stonepine Capital Management LLC owned 3.43% of Surrozen worth $1,318,000 at the end of the most recent reporting period. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Recommended Stories

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.